Potentiation of Antiproliferative Drug Activity by Lonidamine in Hepatocellular Carcinoma Cells

Journal of Chemotherapy

Volumn 15, Issue 5, 2003, Pages 480-487

  Ricotti, L ^a   Tesei, A ^a   De Paola, F ^b   Milandri, C ^b   Amadori, D ^b   Frassineti, G L ^b   Ulivi, P ^a   Zoli, W ^b  

^a ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

Apoptosis; Cell cycle; Hepatocarcinoma; Lonidamine; Modulation by lonidamine

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; FLUOROURACIL; LONIDAMINE; MITOMYCIN C; PACLITAXEL; SULFORHODAMINE B;

ARTICLE; CARCINOMA CELL; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL FRACTIONATION; CELL PROLIFERATION; CELL REGENERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; METAPHASE; MICROTUBULE; MITOSIS INHIBITION;

EID: 0142154949     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.5.480     Document Type: Article

References (40)

1. Bergsland EK, Venook AP. Hepatocellular carcinoma. Curr Opin Oncol 2000; 12: 357-361.
2. Ngan H. Lipiodol computerized tomography: how sensitive and specific is the technique in the diagnosis of hepatocellular carcinoma? Br J Radiol 1990; 63: 771-775.
3. Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 331: 1547-1552.
4. Zhou XD, Tang ZY, Yu YQ et al. Long-term survivors after resection for primary liver cancer. Cancer 1989; 63: 2201-2206.
5. Castells A, Bruix J, Ayuso C et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109: 917-922.
6. Venook AP, Stagg RJ, Lewis BJ et al. Chemoembolization for hepatocellular carcinoma. J Clin Oncol 1990; 8: 1108-1114.
7. Groupe D'Etude et de Traitement du Carcinome Hepatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-1261.
8. Park JG, Lee SK, Hong IG et al. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst 1994; 86: 700-705.
9. Johnson PJ, Dobbs N, Kalayci C et al. Clinical efficacy and toxicity of standard dose Adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer 1992; 65: 751-755.
10. Schachschal G, Lochs H, Plauth M. Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2000; 12: 281-284.
11. Van Eeden H, Falkson G, Burger W, Ansell SM. 5-Fluorouracil and leucovorin in hepatocellular carcinoma. Ann Oncol 1992; 3: 404-405.
12. Patt YZ, Charnsangaveg C, Yoffe B et al. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 1994; 12: 1204-1211.
13. Bobbio-Pallavicini E, Porta C, Moroni M et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients. Eur J Cancer 1997; 33: 1784-1788.
14. Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000; 92: 1042-1053.
15. Dogliotti L, Berruti A, Buniva T et al. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J Clin Oncol 1996; 14: 1165-1172.
16. Nistico C, Garufi C, Milella M et al. Weekly epirubicin plus lonidamine in advanced breast carcinoma. Breast Cancer Res Treat 1999; 56: 233-237.
17. Savini S, Zoli W, Nanni O et al. In vitro potentation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines. Breast Cancer Res Treat 1992; 24: 27-34.
18. Amadori D, Frassineti GL, De Matteis A et al. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial. Breast Cancer Res Treat 1998; 49: 209-217.
19. Orlandi L, Zaffaroni N, Gornati D, Veneroni S, Silvestrini R. Potentation of cisplatin cytotoxicity by lonidamine in primary cultures of human ovarian cancer. Anticancer Res 1994; 14: 1161-1164.
20. Orlandi L, Zaffaroni N, Bearzatto, Villa R, De Marco C, Silvestrini R. Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis. Int J Cancer 1998; 78: 377-384.
21. De Lena M, Lorusso V, Bottalico C et al. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum. J Clin Oncol 1997; 15: 3208-3213.
22. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979; 282: 615-616.
23. Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxic assay for anticancer drug screening. J Natl Cancer Inst 1990; 13: 1107-1112.
24. Horikoshi N, Inoue K, Aiba K, T et al. Phase I study of paclitaxel. Jpn J Cancer Chemother 1994; 21: 2407-2414.
25. Lankelma J, Stuurman M, van Hoogenhuijze J et al. The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration. Eur J Clin Oncol 1988; 24: 175-180.
26. Camaggi CM, Strocchi E, Tamassia V et al. Pharmacokinetic studies of 4′-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases. Cancer Treat Rep 1982; 66: 1819-1824.
27. Findlay MP, Raynaud F, Cuningham D, Iveson A, Collins DJ, Leach MO. Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-alpha. Ann Oncol 1996; 7: 47-53.
28. Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 1995; 15: 393-398.
29. Newell DR, Mansi J, Hardy J et al. The pharmacokinetics of oral lonidamine in breast and lung cancer patients. Semin Oncol 1991; 18: 11-17.
30. Monks A, Scudiero D, Skehan P et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83: 757-766.
31. Kern DH, Morgan CR, Hildebrand-Zanki SU. In vitro pharmacodynamics of 1-β-D-arabinofuranosylcytosine: synergy of antitumour activity with cis-diamminedichloroplatinum(II). Cancer Res 1988; 48: 117-121.
32. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 1998; 41: 385-390.
33. Flickinger JC, Carr BI, Lotze MT. Cancer of the liver. In: Devita VT, ed. Cancer: principles and practice of oncology. 5th ed. New York: Lippincot Company. 1997: 1087-1128.
34. Strumberg D, Erhard J, Harstrick A et al. Phase I of a weekly 1h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma. Eur J Cancer 1998; 34: 1290-1292.
35. Lui WY, Chang YF, Li LL et al. Differential paclitaxel-induced cytotoxicity in rodent and human hepatoma cell lines. Anticancer Res 1998; 18: 3339-3345.
36. Gagandeep S, Novikoff PM, Ott M, Gupta S. Paclitaxel shows cytotoxicity activity in human hepatocellular carcinoma cell lines. Cancer Lett 1999; 136: 109-118.
37. Ussat S, Werner UE, Kruse ML et al. Upregulation of p21 (WAF1/Cip1) precedes tumor necrosis factor-induced necrosis-like cell death. Biochem Biophys Res Commun 2002; 294: 672-679.
38. Chen X, Zhang W, Gao YF, Su XQ, Zhai ZH. Senescence-like changes induced by expression of p21 (waf1/Cip1) in NIH3T3 cell line. Cell Res 2002; 12: 229-233
39. Floridi A, Paggi MG, D'Atri S et al. Effect of lonidamine on the energy metabolism of Ehrlich ascite tumor cells. Cancer Res 1981; 41: 4661-4666.
40. Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De Martino C. Lonidamine, a selective inhibitor of murine cancer cells. J Natl Cancer Inst 1981; 66: 497-499.